Impact of Metabolic Syndrome And Metabolic Syndrome Components
on Tumor Aggresiveness of Renal Cell Carcinoma
Objective: The objective of this study was to evaluate the
effects of Metabolic Syndrome (MetS) and MetS components on tumor size,
Fuhrman grade and pathological T stage in renal cell carcinoma (RCC).
Materials and Methods: The data of 151 patients who were
operated for RCC between January 2010 and April 2018 were
retrospectively reviewed according to the he National Cholesterol
Education Program Adult Treatment Panel III (NCEP ATP III), and the
effects of MetS and its components on tumor size, Fuhrman grade and
pathological T stage were comparatively investigated.
Results: Of the 151 patients operated for RCC in our clinic,
27.2% had MetS, 29.1% had diabetes mellitus (DM), 41% had
hypertension (HT), 68.3% had low high-density lipoprotein (HDL), 41%
had elevated triglyceride (TGL) elevation, and 27.2% had obesity. It
was found that the size of the tumor was statistically significantly
increased in the presence of the metabolic criteria examined. There was
a statistically significant increase in the Fuhrman grade of the
patients with MetS, DM, low HDL, high TGL and obesity. In the presence
of clinical conditions such as HT, low HDL and high TGL, there was a
statistically significant increase in the pathological T stage.
Conclusion: In patients undergoing surgery for RCC, MetS and
its components had a statistically significant correlation with tumor
size, Fuhrman grade, and pathological stage. If our results are
supported by further studies, the correlation between MetS and RCC could
be revealed more clearly.
Keywords: Renal cell carcinoma, Metabolic Syndrome, Diabetes
mellitus, Hypertension